Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acomplia Indications To Be Reviewed By Separate FDA Divisions, Sanofi Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis' weight loss/smoking cessation agent Acomplia (rimonabant) will be concurrently reviewed by two separate divisions within FDA's Office of New Drugs, Exec VP-Pharmaceutical Operations Hanspeter Spek said May 13 during the company's earnings call

You may also be interested in...



Acomplia Is "Not Approvable" For Smoking Cessation, "Approvable" For Weight Loss

FDA issued a split decision for Sanofi-Aventis' rimonabant NDAs.

Acomplia Is "Not Approvable" For Smoking Cessation, "Approvable" For Weight Loss

FDA issued a split decision for Sanofi-Aventis' rimonabant NDAs.

Sanofi-Aventis Eyes Summer Launch For Ambien CR

Discussions with FDA following an "approvable" letter for the sleep therapy have revolved around labeling for treatment duration, the company says. A summer launch would put Ambien CR's introduction several months behind that of Sepracor's Lunesta, which entered the insomnia market in early April.

Topics

UsernamePublicRestriction

Register

PS062199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel